We identified pregnenolone and irinotecan as compounds that can upregulate ORM1 and OVGP1, respectively, and showed that these agents inhibit MM cell viability in vitro, while restoring the expression of their target proteins. This evidence concerns the gene ORM1 and Miyoshi myopathy.